The data presented here suggest that albumin Cys34 thiol oxidation has the potential to be a useful robust blood biomarker of dystropathology and may be used to efficiently evaluate and advance the development of therapies for DMD. The gene discussed is ALB; the disease is Duchenne muscular dystrophy.